Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
ConditionAtopic Dermatitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-65
SponsorBoston Children's Hospital
About this trial
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female participants ≥6 to 65 yrs of age
Meet AD Standard Diagnostic Criteria
Disqualifiers
Enrollment in another clinical trial
Hypersensitivity to an agent used for the skin decolonization protocol
Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
Phototherapy for AD within 4 weeks
Trial population
atopic dermatitis
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
atopic dermatitis severity
validated assessment EASI score
Time frame
baseline, only 1 time pointSponsors and contacts
Click on the lead sponsor to view all of their trials.
Boston Children's Hospital
Lead sponsor
Harvard Medical School (HMS and HSDM)
Sponsor institution
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Source ClinicalTrials.gov